Key Highlights
- Net revenues for the fiscal first quarter ended September 30, 2026 rose 10.6% to USD 18,682,000 from USD 16,887,000, with homecare Revenue up 17.6% to USD 17,506,000 on more sales representatives and higher productivity.
- Operating income climbed 30.7% to USD 3,489,000, or 18.7% of net revenues, while gross Margin improved to 80.0% from 78.1% on revenue mix, and Net Income rose 29.3% to USD 2,761,000.
- Diluted earnings per share were USD 0.32 against USD 0.25 a year earlier, and management said this is the 16th consecutive quarter of year-over-year growth in both revenue and operating income.
- Electromed repurchased 157,341 shares for about USD 4.3 million in the quarter, and cash fell to USD 15,875,000 from USD 20,450,000 at June 30, 2026, with no Debt shown on the balance sheet.
Homecare Strength Offsets Weak Hospital and Distributor Sales
Electromed (NYSEAMERICAN:ELMD) filed its Form 10-Q for the quarter ended September 30, 2026 on November 10, 2026, the same day as its earnings call. The company makes the SmartVest airway clearance system, which uses high frequency chest wall oscillation to help move mucus for patients with conditions such as bronchiectasis and cystic fibrosis. Homecare, about 94% of sales according to management, grew USD 2,617,000. Hospital revenue fell 31.6% to USD 716,000 because large Capital purchases in the prior-year period did not repeat, and homecare distributor revenue dropped 55.9% to USD 366,000 on timing of distributor purchases. Management said the company averaged 63 homecare field sales representatives.
Operating Leverage Lifts Profit Faster Than Sales
Gross profit rose to USD 14,937,000, and the filing credits the higher margin to mix, as high-value homecare grew while lower-margin non-home care sales declined. Selling, general and administrative expenses rose 8.6% to USD 11,171,000, with Payroll costs up 7.8% to USD 7,413,000, and Research and Development rose 14.9% to USD 277,000. Because costs grew more slowly than revenue, Operating Income outpaced sales growth. Income tax expense was USD 876,000 at an effective rate of 24.1%, and net income was USD 2,761,000. Management said annualized homecare revenue per weighted average direct sales representative was USD 1,109,000, just above the midpoint of its fiscal 2027 target range of USD 1,050,000 to USD 1,150,000. The filing and call gave no revenue or earnings guidance.
Cash Returned to Shareholders, Payer Access and a CEO Handover
Operating cash flow was USD 373,000 because accrued compensation fell USD 3,241,000, a normal first-quarter payout. Financing used USD 4,746,000, mostly the USD 4,328,000 share repurchase. Cash, Accounts Receivable of USD 30,267,000 and shareholders' Equity of USD 52,473,000 anchor the balance sheet. On the call, management said 87% of covered lives in the United States are under payer contract, 48% of orders came through its electronic prescribing system, and it renewed a contract with the largest hospital purchasing organization in the country. Management also reiterated that its chief executive expects to retire in April 2027 and that a board succession plan is underway. Risks include distributor inventory levels, reimbursement rules and the dependence on homecare.
Where Things Stand
Possibly, but one quarter does not confirm it. Electromed (NYSEAMERICAN:ELMD) extended its run to 16 consecutive quarters of higher revenue and operating income, with homecare strength lifting operating income 30.7% on 10.6% revenue growth. Weaker hospital and distributor sales, a USD 4.6 million drop in cash after Buybacks and a pending chief executive retirement in April 2027 are the counterweights. Next markers are homecare revenue per representative against the target range, distributor inventory normalizing and the choice of a successor.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...